The introduction of value-based payment models means that the goals of providing optimal patient care have become aligned for the clinician and the insurer, leading to more cooperation and support, said Roy Beveridge, MD, chief medical officer of Humana. This represents a shift from the more adversarial relationship between physicians and payers that existed under fee-for-service models.
The introduction of value-based payment models means that the goals of providing optimal patient care have become aligned for the clinician and the insurer, leading to more cooperation and support, said Roy Beveridge, MD, chief medical officer of Humana. This represents a shift from the more adversarial relationship between physicians and payers that existed under fee-for-service models.
Transcript (slightly modified)
What has been the physician reaction to the increase in value-based payment models?
Traditionally, fee-for-service physicians have had very negative interactions with their payer, because there’s an adversarial relationship that’s set up in that relationship. When you move to a value relationship, there is a complete alignment between what’s best for the patient is actually what’s really good for the clinician, and the insurer, the payer, becomes a source of support to allow the provider to take care of the patient.
You see that in data, you see that in analytics, you see that in programs. So a small physician group can’t have nurses that go in and take care of their patients for translation services or pharmacy medication programs. That’s where companies like Humana do it and do it really well.
Impact of Amivantamab-Lazertinib on EGFR, MET Resistance Alterations in NSCLC: Danny Nguyen, MD
September 15th 2025The combination of amivantamab and lazertinib in first-line non–small cell lung cancer (NSCLC) significantly reduces resistance mechanisms with implications for second-line treatment, said Danny Nguyen, MD, of City of Hope.
Read More
Disparities in Biomarker Testing Impact Nonsquamous NSCLC Outcomes: Surbhi Singhal, MD
September 6th 2025Surbhi Singhal, MD, of the University of California Davis, discussed disparities in biomarker testing among patients diagnosed with stage IV nonsquamous non–small cell lung cancer (NSCLC).
Read More